Avalo Therapeutics (AVTX) Non-Current Debt (2014 - 2023)

Avalo Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $10.5 million in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Debt changed N/A year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2023 stood at $10.5 million (changed N/A YoY), and the FY2022 full-year result was $13.5 million, down 58.93% from the prior year.
• Non-Current Debt for Q1 2023 stood at $10.5 million, down from $13.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $32.8 million in Q4 2021, with the low at $10.5 million in Q1 2023.
• Historically, Non-Current Debt has averaged $16.9 million across 4 years, with a median of $14.3 million in 2019.
• Annual changes were most pronounced in 2019 — Non-Current Debt declined 0.68% — and 2022, when it tumbled 58.93%.
• Avalo Therapeutics' Non-Current Debt stood at $14.3 million in 2019, then soared by 130.33% to $32.8 million in 2021, then sank by 58.93% to $13.5 million in 2022, then decreased by 22.36% to $10.5 million in 2023.
• The last three Non-Current Debt figures came in at $10.5 million (Q1 2023), $13.5 million (Q4 2022), and $16.5 million (Q3 2022), per Business Quant data.